Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses


Supernus Pharmaceuticals reported $133.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Corcept Therapeutics USD 142.04M 14.86M Sep/2026
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Pacira USD 950.8M 858.99M Sep/2026
Perrigo USD 271.7M 3.01B Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026